Home › Companies › CGON

CG Oncology

Market cap $7.05B 89.3M shares (10-Q, Nov 4, 2026) × $78.94 close Nov 17, 2026

Most recent annual filing: 2026-02-15

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. CORE-008 Cohort CX / BOND-003Dec 2026CORE-008 Cohort CX / BOND-003, Dec 2026, notable
  2. BCG-unresponsive BLA filingMar 2027BCG-unresponsive BLA filing, Mar 2027, notable
  3. Intermediate-risk / HG Ta NMIBC2Q 2027Intermediate-risk / HG Ta NMIBC, 2Q 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (1 active programs)

Capital (as filed)

Cash
$28.2M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$956M Sep 30, 2026
Operating cash flow
−$47.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$985M cash, runway through 2029 per the update of Nov 6, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (9)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (9 calls)

Every verdict Biotech Distilled has published on CG Oncology, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Buy core CG Oncology (CGON): Scientific Deep Dive for Creto and Pipeline Products Best-in-class Phase 3 data (75.5% CR), clean safety profile (0% Grade 3+ TRAEs), fortress cash position, resolved legal overhang, and strong M&A appeal make CGON a high-conviction buy on pullbacks.
  2. Buy core UPDATE: CG Oncology (CGON) - EoY Update Balance sheet transformed to near-$1B fortress after aggressive ATM execution, financing overhang thesis dead, and core thesis strengthened ahead of PIVOT-006 and BLA submission.
  3. Buy core UPDATE: CG Oncology (CGON) — Q1 2026 Status Check ATM fully drawn at $57.56 average closing the dilution overhang, BLA on defined Q4 2026 path, and two near-term catalysts (AUA May 16 combo data and PIVOT-006 topline) support maintaining the position.
  4. Buy core UPDATE: CG Oncology (CGON) — The Gem Combo Clears the Bar CORE-008 Cohort CX posted 85.7%/92.3% CR with 0% Grade 3+ TRAEs, validating the combination platform and reducing the 'creatures of habit' launch risk, while PIVOT-006 remains the next major catalyst.
  5. Buy core UPDATE: CG Oncology (CGON) — The COO Walks, the CEO Doubles Up Clinical platform and balance sheet remain intact despite COO departure; 7.5% drawdown into clean combo data may be an attractive entry, though launch-readiness risk has increased with the CCO seat open heading into PIVOT-006.
  6. Buy core UPDATE: CG Oncology (CGON) — The ATM Reloads at $72 ANI post-trial motions denied closing the legal overhang, BOND-003 peer-reviewed in The Lancet with stronger durability metrics, and PIVOT-006 topline imminent, though a new $500M ATM at $72 and accelerating burn are partial offsets.
  7. Buy core UPDATE: CG Oncology (CGON) - The Commercial Chair Is Filled CCO vacancy filled by Isabel Kalofonos, a multi-launch specialist oncology veteran, closing the launch-readiness gap opened by the COO's departure, while clinical platform and legal picture remain intact.
  8. Buy core UPDATE: CG Oncology (CGON) - The Readout Gets a Month PIVOT-006 topline pinned to November 2026, Q3 burn lighter than modeled, fortress balance sheet intact, though ANI appeal is now live at Delaware Supreme Court and the $500M ATM sits above the tape.
  9. Buy core UPDATE: CG Oncology (CGON) - The House Is Fireproofed PIVOT-006 hit its primary endpoint with HR 0.32 (p<0.0001), a 68% recurrence risk reduction in a randomized Phase 3, validating the backbone therapy framing and supporting a re-rating, with first BLA slipping one quarter to March 2027 for a broader label.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (3 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (24)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 8, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

8 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)